Please try another search
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research and development and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anpingxi, an antibody drug and anti-tumor product; Anjiayin for the treatment of hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and SCTV01C and SCTV01E, which are mutant strain recombinant protein vaccines. Its product pipeline includes SCT630 used for the treatment of autoimmune diseases; SCT510 for treating solid tumors; SCT-I10A, a monoclonal antibody injection, which is in phase 3 trials for the treatment of solid tumors; SCTV01 vaccine for the treatment of corona virus; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000 for the treatment of human papillomavirus, as well as SCTA01, which is in phase 2/3 clinical research trials for treating SARS COV-2. The company was founded in 2002 and is based in Beijing, China. Sinocelltech Group Limited is a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
| Name | Age | Since | Title |
|---|---|---|---|
| Wei He | 56 | - | Independent Director |
| Yang Wang | 66 | 2010 | Deputy GM & Director |
| Liangzhi Xie | 59 | 2019 | Chairman of the Board & GM |
| Li Ming Tang | 45 | 2018 | Deputy GM, Secretary of the Board & Director |
| Xun Li | 46 | 2025 | Chairman of the Supervisory Committee & Director |
| Haofeng Wang | - | 2025 | Independent Director |
| Lingyun Jia | - | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review